

# James J Dinicolantonio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6170292/publications.pdf>

Version: 2024-02-01

144  
papers

4,754  
citations

101543

36  
h-index

114465

63  
g-index

144  
all docs

144  
docs citations

144  
times ranked

8204  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ferulic acid and berberine, via Sirt1 and AMPK, may act as cell cleansing promoters of healthy longevity. <i>Open Heart</i> , 2022, 9, e001801.	2.3	20
2	Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. <i>Open Heart</i> , 2022, 9, e001989.	2.3	19
3	Coenzyme Q10 deficiency can be expected to compromise Sirt1 activity. <i>Open Heart</i> , 2022, 9, e001927.	2.3	2
4	Maintaining Effective Beta Cell Function in the Face of Metabolic Syndrome-Associated Glucolipotoxicity—Nutraceutical Options. <i>Healthcare (Switzerland)</i> , 2022, 10, 3.	2.0	1
5	Nutraceuticals/Drugs Promoting Mitophagy and Mitochondrial Biogenesis May Combat the Mitochondrial Dysfunction Driving Progression of Dry Age-Related Macular Degeneration. <i>Nutrients</i> , 2022, 14, 1985.	4.1	10
6	A Fundamental Role for Oxidants and Intracellular Calcium Signals in Alzheimer’s Pathogenesis—And How a Comprehensive Antioxidant Strategy May Aid Prevention of This Disorder. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2140.	4.1	11
7	Melatonin may decrease risk for and aid treatment of COVID-19 and other RNA viral infections. <i>Open Heart</i> , 2021, 8, e001568.	2.3	11
8	A nutraceutical strategy for downregulating TGF $\beta$ 2 signalling: prospects for prevention of fibrotic disorders, including post-COVID-19 pulmonary fibrosis. <i>Open Heart</i> , 2021, 8, e001663.	2.3	6
9	Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors. <i>Open Heart</i> , 2021, 8, e001655.	2.3	6
10	High Intakes of Bioavailable Phosphate May Promote Systemic Oxidative Stress and Vascular Calcification by Boosting Mitochondrial Membrane Potential—Is Good Magnesium Status an Antidote?. <i>Cells</i> , 2021, 10, 1744.	4.1	9
11	Low-grade metabolic acidosis as a driver of insulin resistance. <i>Open Heart</i> , 2021, 8, e001788.	2.3	2
12	Nutraceutical Strategies for Suppressing NLRP3 Inflammasome Activation: Pertinence to the Management of COVID-19 and Beyond. <i>Nutrients</i> , 2021, 13, 47.	4.1	37
13	Low-grade metabolic acidosis as a driver of chronic disease: a 21st century public health crisis. <i>Open Heart</i> , 2021, 8, e001730.	2.3	9
14	The Flaws of Recent Omega-3 Clinical Trials Should Not Prevent Their Use. <i>Missouri Medicine</i> , 2021, 118, 322.	0.3	0
15	Relationships between hyperinsulinaemia, magnesium, vitamin D, thrombosis and COVID-19: rationale for clinical management. <i>Open Heart</i> , 2020, 7, e001356.	2.3	49
16	Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. <i>Open Heart</i> , 2020, 7, e001350.	2.3	29
17	The Importance of Marine Omega-3s for Brain Development and the Prevention and Treatment of Behavior, Mood, and Other Brain Disorders. <i>Nutrients</i> , 2020, 12, 2333.	4.1	53
18	Targeting Casein kinase 2 with quercetin or enzymatically modified isoquercitrin as a strategy for boosting the type 1 interferon response to viruses and promoting cardiovascular health. <i>Medical Hypotheses</i> , 2020, 142, 109800.	1.5	9

#	ARTICLE	IF	CITATIONS
19	Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase. <i>Open Heart</i> , 2020, 7, e001337.	2.3	49
20	Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. <i>Medical Hypotheses</i> , 2020, 143, 110051.	1.5	21
21	Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 383-385.	3.1	118
22	The benefits of marine omega-3s for preventing arrhythmias. <i>Open Heart</i> , 2020, 7, e000904.	2.3	6
23	Effects of spirulina on weight loss and blood lipids: a review. <i>Open Heart</i> , 2020, 7, e001003.	2.3	37
24	Azithromycin and glucosamine may amplify the type 1 interferon response to RNA viruses in a complementary fashion. <i>Immunology Letters</i> , 2020, 228, 83-85.	2.5	5
25	The Ability of Carnitine to Act as a Type 1 Histone Deacetylase Inhibitor May Explain the Favorable Impact of Carnitine Supplementation on Mitochondrial Biogenesis in the Elderly. <i>Medical Research Archives</i> , 2020, 8, .	0.2	4
26	The Benefits of Omega-3 Fats for Stabilizing and Remodeling Atherosclerosis. <i>Missouri Medicine</i> , 2020, 117, 65-69.	0.3	4
27	The Importance of Maintaining a Low Omega-6/Omega-3 Ratio for Reducing the Risk of Inflammatory Cytokine Storms. <i>Missouri Medicine</i> , 2020, 117, 539-542.	0.3	2
28	A diet rich in taurine, cysteine, folate, B12 and betaine may lessen risk for Alzheimer's disease by boosting brain synthesis of hydrogen sulfide. <i>Medical Hypotheses</i> , 2019, 132, 109356.	1.5	29
29	Dietary fats, blood pressure and artery health. <i>Open Heart</i> , 2019, 6, e001035.	2.3	2
30	Sea Change for Marine Omega-3s. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2524-2533.	3.0	24
31	Activated glycine receptors may decrease endosomal NADPH oxidase activity by opposing CLC-3-mediated efflux of chloride from endosomes. <i>Medical Hypotheses</i> , 2019, 123, 125-129.	1.5	9
32	Importance of maintaining a low omega-6/omega-3 ratio for reducing platelet aggregation, coagulation and thrombosis. <i>Open Heart</i> , 2019, 6, e001011.	2.3	34
33	Autophagy-induced degradation of Notch1, achieved through intermittent fasting, may promote beta cell neogenesis: implications for reversal of type 2 diabetes. <i>Open Heart</i> , 2019, 6, e001028.	2.3	19
34	Does elevated bilirubin aid weight control by preventing development of hypothalamic leptin resistance?. <i>Open Heart</i> , 2019, 6, e000897.	2.3	4
35	Association of moderately elevated trimethylamine N-oxide with cardiovascular risk: is TMAO serving as a marker for hepatic insulin resistance. <i>Open Heart</i> , 2019, 6, e000890.	2.3	30
36	Astaxanthin plus berberine: a nutraceutical strategy for replicating the benefits of a metformin/fibrate regimen in metabolic syndrome. <i>Open Heart</i> , 2019, 6, e000977.	2.3	3

#	ARTICLE	IF	CITATIONS
37	Editorial commentary: Coffee, tea, and cardiovascular morbidity and mortality. Trends in Cardiovascular Medicine, 2019, 29, 351-352.	4.9	3
38	Glucosamine for the Treatment of Osteoarthritis: The Time Has Come for Higher-Dose Trials. Journal of Dietary Supplements, 2019, 16, 179-192.	2.6	16
39	Coffee for Cardioprotection and Longevity. Progress in Cardiovascular Diseases, 2018, 61, 38-42.	3.1	58
40	Evidence, Not Evangelism, for Dietary Recommendations. Mayo Clinic Proceedings, 2018, 93, 138-144.	3.0	7
41	Thiamine and Cardiovascular Disease: A Literature Review. Progress in Cardiovascular Diseases, 2018, 61, 27-32.	3.1	72
42	Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis. Open Heart, 2018, 5, e000668.	2.3	166
43	Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health: A Comprehensive Review. Progress in Cardiovascular Diseases, 2018, 61, 76-85.	3.1	60
44	Sugar addiction: is it real? A narrative review. British Journal of Sports Medicine, 2018, 52, 910-913.	6.7	59
45	Fructose-induced inflammation and increased cortisol: A new mechanism for how sugar induces visceral adiposity. Progress in Cardiovascular Diseases, 2018, 61, 3-9.	3.1	79
46	Importance of maintaining a low omega-6/omega-3 ratio for reducing inflammation. Open Heart, 2018, 5, e000946.	2.3	118
47	Copper deficiency may be a leading cause of ischaemic heart disease. Open Heart, 2018, 5, e000784.	2.3	75
48	Minimizing Membrane Arachidonic Acid Content as a Strategy for Controlling Cancer: A Review. Nutrition and Cancer, 2018, 70, 840-850.	2.0	15
49	Antioxidant bilirubin works in multiple ways to reduce risk for obesity and its health complications. Open Heart, 2018, 5, e000914.	2.3	26
50	In Critique of "In Defense of Sugar": The Nuance of Whole Foods. Progress in Cardiovascular Diseases, 2018, 61, 384-385.	3.1	2
51	Role of dietary histidine in the prevention of obesity and metabolic syndrome. Open Heart, 2018, 5, e000676.	2.3	35
52	The fructose-copper connection: Added sugars induce fatty liver and insulin resistance via copper deficiency. Journal of Insulin Resistance, 2018, 3, .	1.3	3
53	Dietary Glycine Is Rate-Limiting for Glutathione Synthesis and May Have Broad Potential for Health Protection. Ochsner Journal, 2018, 18, 81-87.	1.1	33
54	Not Salt But Sugar As Aetiological In Osteoporosis: A Review. Missouri Medicine, 2018, 115, 247-252.	0.3	7

#	ARTICLE	IF	CITATIONS
55	The History of the Salt Wars. American Journal of Medicine, 2017, 130, 1011-1014.	1.5	11
56	Is Salt a Culprit or an Innocent Bystander in Hypertension? A Hypothesis Challenging the Ancient Paradigm. American Journal of Medicine, 2017, 130, 893-899.	1.5	7
57	Interleukin-1beta may act on hepatocytes to boost plasma homocysteine – The increased cardiovascular risk associated with elevated homocysteine may be mediated by this cytokine. Medical Hypotheses, 2017, 102, 78-81.	1.5	4
58	Statins, Ezetimibe, and Proprotein Convertase Subtilisin–Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events. American Journal of Cardiology, 2017, 119, 565-571.	1.6	14
59	Neuroprotective potential of high-dose biotin. Medical Hypotheses, 2017, 109, 145-149.	1.5	24
60	Targeting aspirin resistance with nutraceuticals: a possible strategy for reducing cardiovascular morbidity and mortality. Open Heart, 2017, 4, e000642.	2.3	2
61	Added sugars drive coronary heart disease via insulin resistance and hyperinsulinaemia: a new paradigm. Open Heart, 2017, 4, e000729.	2.3	11
62	Boosting endogenous production of vasoprotective hydrogen sulfide via supplementation with taurine and N-acetylcysteine: a novel way to promote cardiovascular health. Open Heart, 2017, 4, e000600.	2.3	38
63	Supplemental N-acetylcysteine and other measures that boost intracellular glutathione can downregulate interleukin-1 $\beta$ signalling: a potential strategy for preventing cardiovascular events?. Open Heart, 2017, 4, e000599.	2.3	0
64	The Microvascular and Macrovascular Benefits of Fibrates in Diabetes and the Metabolic Syndrome: A review. Missouri Medicine, 2017, 114, 464-471.	0.3	6
65	Suppression of NADPH Oxidase Activity May Slow the Expansion of Osteolytic Bone Metastases. Healthcare (Switzerland), 2016, 4, 60.	2.0	5
66	Increase in the intake of refined carbohydrates and sugar may have led to the health decline of the Greenland Eskimos: Table A1. Open Heart, 2016, 3, e000444.	2.3	8
67	Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart, 2016, 3, e000473.	2.3	87
68	Pentoxifylline for vascular health: a brief review of the literature. Open Heart, 2016, 3, e000365.	2.3	90
69	Evidence from randomised controlled trials does not support current dietary fat guidelines: a systematic review and meta-analysis. Open Heart, 2016, 3, e000409.	2.3	54
70	The importance of a balanced 6 to 3 ratio in the prevention and management of obesity. Open Heart, 2016, 3, e000385.	2.3	96
71	Added sugars drive nutrient and energy deficit in obesity: a new paradigm. Open Heart, 2016, 3, e000469.	2.3	30
72	Hypertension Due to Toxic White Crystals in the Diet: Should We Blame Salt or Sugar?. Progress in Cardiovascular Diseases, 2016, 59, 219-225.	3.1	27

#	ARTICLE	IF	CITATIONS
73	The Evidence for Saturated Fat and for Sugar Related to Coronary Heart Disease. Progress in Cardiovascular Diseases, 2016, 58, 464-472.	3.1	242
74	Preventing Cardiovascular Disease. Progress in Cardiovascular Diseases, 2016, 58, 463.	3.1	2
75	Dietary Salt Restriction in Heart Failure: Where Is the Evidence?. Progress in Cardiovascular Diseases, 2016, 58, 401-406.	3.1	10
76	Lifestyle Choices Fuel Epidemics of Diabetes and Cardiovascular Disease Among Asian Indians. Progress in Cardiovascular Diseases, 2016, 58, 505-513.	3.1	35
77	Added sugars drive chronic kidney disease and its consequences: A comprehensive review. Journal of Insulin Resistance, 2016, 1, .	1.3	6
78	Problems with the 2015 Dietary Guidelines for Americans:. Missouri Medicine, 2016, 113, 272-273.	0.3	0
79	Problems with the 2015 Dietary Guidelines for Americans: An Alternative. Missouri Medicine, 2016, 113, 93-7.	0.3	4
80	How calorie-focused thinking about obesity and related diseases may mislead and harm public health. An alternative. Public Health Nutrition, 2015, 18, 571-581.	2.2	51
81	Is fructose malabsorption a cause of irritable bowel syndrome?. Medical Hypotheses, 2015, 85, 295-297.	1.5	30
82	Added Fructose. Mayo Clinic Proceedings, 2015, 90, 372-381.	3.0	132
83	Evidence from randomised controlled trials did not support the introduction of dietary fat guidelines in 1977 and 1983: a systematic review and meta-analysis. Open Heart, 2015, 2, e000196.	2.3	128
84	Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open Heart, 2015, 2, e000205.	2.3	33
85	Meta-Analysis of Randomized Controlled Trials and Adjusted Observational Results of Use of Clopidogrel, Aspirin, and Oral Anticoagulants in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2015, 115, 1185-1193.	1.6	65
86	Evidence-based diuretics: focus on chlorthalidone and indapamide. Future Cardiology, 2015, 11, 203-217.	1.2	18
87	β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart, 2015, 2, e000230.	2.3	77
88	An increased need for dietary cysteine in support of glutathione synthesis may underlie the increased risk for mortality associated with low protein intake in the elderly. Age, 2015, 37, 96.	3.0	65
89	In reply“Fructose as a Driver of Diabetes: An Incomplete View of the Evidence. Mayo Clinic Proceedings, 2015, 90, 988-990.	3.0	6
90	Capsaicin may have important potential for promoting vascular and metabolic health: Table 1. Open Heart, 2015, 2, e000262.	2.3	100

#	ARTICLE	IF	CITATIONS
91	Combining Rosuvastatin With Angiotensin-Receptor Blockers of Different PPAR $\beta$ -Activating Capacity. <i>Angiology</i> , 2015, 66, 36-42.	1.8	7
92	The Interaction Between Statins and Exercise: Mechanisms and Strategies to Counter the Musculoskeletal Side Effects of This Combination Therapy. <i>Ochsner Journal</i> , 2015, 15, 429-37.	1.1	19
93	Red Yeast Rice Plus Berberine: Practical Strategy for Promoting Vascular and Metabolic Health. <i>Alternative Therapies in Health and Medicine</i> , 2015, 21 Suppl 2, 40-5.	0.0	8
94	Perindopril for improving cardiovascular events. <i>Vascular Health and Risk Management</i> , 2014, 10, 539.	2.3	1
95	Hypertension: empirical evidence and implications in 2014. <i>Open Heart</i> , 2014, 1, e000048.	2.3	22
96	Is concomitant aspirin helping novel oral anticoagulants? Focus on apixaban. <i>Open Heart</i> , 2014, 1, e000134.	2.3	0
97	It Takes the Right Medications to Prevent a Million Heart Attacks and Strokes. <i>Postgraduate Medicine</i> , 2014, 126, 164-167.	2.0	0
98	The wrong white crystals: not salt but sugar as aetiological in hypertension and cardiometabolic disease. <i>Open Heart</i> , 2014, 1, e000167.	2.3	81
99	Omega-3 Fatty Acids: A Growing Ocean of Choices. <i>Current Atherosclerosis Reports</i> , 2014, 16, 389.	4.8	21
100	Meta-Analysis Comparing Carvedilol Versus Metoprolol for the Prevention of Postoperative Atrial Fibrillation Following Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2014, 113, 565-569.	1.6	35
101	Optimal aspirin dose in acute coronary syndromes: an emerging consensus. <i>Future Cardiology</i> , 2014, 10, 291-300.	1.2	8
102	A Higher Dietary Ratio of Long-Chain Omega-3 to Total Omega-6 Fatty Acids for Prevention of COX-2-Dependent Adenocarcinomas. <i>Nutrition and Cancer</i> , 2014, 66, 1279-1284.	2.0	22
103	An Unsavory Truth: Sugar, More than Salt, Predisposes to Hypertension and Chronic Disease. <i>American Journal of Cardiology</i> , 2014, 114, 1126-1128.	1.6	14
104	Clinical Outcomes with $\beta$ -Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials. <i>American Journal of Medicine</i> , 2014, 127, 939-953.	1.5	224
105	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 63, 607.	2.8	3
106	Bioavailable dietary phosphate, a mediator of cardiovascular disease, may be decreased with plant-based diets, phosphate binders, niacin, and avoidance of phosphate additives. <i>Nutrition</i> , 2014, 30, 739-747.	2.4	21
107	Population-wide Sodium Reduction: Reasons to Resist. <i>Mayo Clinic Proceedings</i> , 2014, 89, 426-427.	3.0	2
108	Omega-3 and Prostate Cancer: Examining the Pertinent Evidence. <i>Mayo Clinic Proceedings</i> , 2014, 89, 444-450.	3.0	12

#	ARTICLE	IF	CITATIONS
109	The Reply. American Journal of Medicine, 2014, 127, e17.	1.5	7
110	Perindopril vs Enalapril in Patients with Systolic Heart Failure: Systematic Review and Metaanalysis. Ochsner Journal, 2014, 14, 350-8.	1.1	4
111	Omega-3s and cardiovascular health. Ochsner Journal, 2014, 14, 399-412.	1.1	25
112	Effects of Habitual Coffee Consumption on Cardiometabolic Disease, Cardiovascular Health, and All-Cause Mortality. Journal of the American College of Cardiology, 2013, 62, 1043-1051.	2.8	305
113	Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial. International Journal of Cardiology, 2013, 168, 4076-4080.	1.7	12
114	Clopidogrel is safer than ticagrelor in regard to bleeds: A closer look at the PLATO trial. International Journal of Cardiology, 2013, 168, 1739-1744.	1.7	50
115	Misrepresentation of vital status follow-up: Challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. International Journal of Cardiology, 2013, 169, 145-146.	1.7	17
116	Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: Challenging PLATO mortality rates. International Journal of Cardiology, 2013, 164, 255-258.	1.7	10
117	Meta-Analysis of Cilostazol Versus Aspirin for the Secondary Prevention of Stroke. American Journal of Cardiology, 2013, 112, 1230-1234.	1.6	45
118	Dietary Sodium Restriction: Take It with a Grain of Salt. American Journal of Medicine, 2013, 126, 951-955.	1.5	32
119	Thiamine Supplementation for the Treatment of Heart Failure: A Review of the Literature. Congestive Heart Failure, 2013, 19, 214-222.	2.0	69
120	Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	92
121	Niacin Therapy Lives for Another Dayâ€”Maybe?. Journal of the American College of Cardiology, 2013, 61, 2197-2198.	2.8	8
122	Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: Insights from the FDA reports. International Journal of Cardiology, 2013, 168, 633-635.	1.7	5
123	In replyâ€”Regarding L-Carnitine and Cardiovascular Disease. Mayo Clinic Proceedings, 2013, 88, 900-901.	3.0	2
124	Challenging the FDA Black Box Warning for High Aspirin Dose With Ticagrelor in Patients With Diabetes. Diabetes, 2013, 62, 669-671.	0.6	13
125	Exploring the Ticagrelor-Statins Interplay in the PLATO Trial. Cardiology, 2013, 124, 105-107.	1.4	17
126	Exploring the reduction in myocardial infarctions in the PLATO trial: Which patients benefited on ticagrelor vs. clopidogrel?. International Journal of Cardiology, 2013, 165, 396-397.	1.7	11



#	ARTICLE	IF	CITATIONS
127	L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2013, 88, 544-551.	3.0	158
128	Refuting the Ticagrelor-Aspirin Black Box Warning: And Proposing a Ticagrelor Early-PCI Black Box Warning. <i>International Journal of Cardiology</i> , 2013, 168, 1721-1723.	1.7	5
129	Not All Angiotensin-Converting Enzyme Inhibitors Are Equal: Focus on Ramipril and Perindopril. <i>Postgraduate Medicine</i> , 2013, 125, 154-168.	2.0	46
130	Statin Wars: The Heavyweight Match-Atorvastatin versus Rosuvastatin for the Treatment of Atherosclerosis, Heart Failure, and Chronic Kidney Disease. <i>Postgraduate Medicine</i> , 2013, 125, 7-16.	2.0	23
131	Clopidogrel, Prasugrel, or Ticagrelor? A Practical Guide to Use of Antiplatelet Agents in Patients With Acute Coronary Syndromes. <i>Postgraduate Medicine</i> , 2013, 125, 91-102.	2.0	41
132	Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2013, 7, 5-9.	2.1	9
133	Chlorthalidone Versus Hydrochlorothiazide. <i>Annals of Internal Medicine</i> , 2013, 158, 920.	3.9	3
134	Effects of thiamine on cardiac function in patients with systolic heart failure: systematic review and metaanalysis of randomized, double-blind, placebo-controlled trials. <i>Ochsner Journal</i> , 2013, 13, 495-9.	1.1	28
135	Omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease: do formulation, dosage & comparator matter?. <i>Missouri Medicine</i> , 2013, 110, 495-8.	0.3	5
136	Do omega-3 fatty acids cause prostate cancer?. <i>Missouri Medicine</i> , 2013, 110, 293-5.	0.3	4
137	Comparing Ticagrelor Versus Clopidogrel in Patients With a History of Cerebrovascular Disease. <i>Stroke</i> , 2012, 43, 3409-3410.	2.0	19
138	Should torsemide be the loop diuretic of choice in systolic heart failure?. <i>Future Cardiology</i> , 2012, 8, 707-728.	1.2	51
139	Mortality in the TRACER and ATLAS ACS 2 Trials: Two More Reasons to Audit Vital Records in PLATO. <i>Cardiology</i> , 2012, 123, 11-14.	1.4	6
140	Hydrochlorothiazide: is it a wise choice?. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 807-814.	1.8	22
141	Angiotensin Receptor Blockers Worsen Renal Function and Dyspnea on Ticagrelor: A Potential Ticagrelor- $\text{Angiotensin Receptor Blocker}$ Interaction?. <i>Clinical Cardiology</i> , 2012, 35, 647-648.	1.8	14
142	Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1101-1111.	1.8	9
143	Carvedilol: a third-generation $\beta^2$ -blocker should be a first-choice $\beta^2$ -blocker. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 13-25.	1.5	31
144	CoQ10 and L-carnitine for statin myalgia?. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1329-1333.	1.5	21